FMP
Q BioMed Inc.
QBIO
PNK
Q BioMed Inc., a biomedical acceleration and development company, focuses on licensing, acquiring, and providing resources to life sciences and healthcare companies. The company offers Strontium Chloride SR89 and Metastron, a radiopharmaceutical therapeutic for the treatment of metastatic bone cancer pain. It is also developing Man-01, a pre-clinical lead candidate for the treatment of primary open angle glaucoma; QBM-001 for rare pediatric non-verbal autism spectrum disorder; and Uttroside-B for liver cancer. Q BioMed Inc. has a partnership with Mannin Research Inc. for the development of therapeutics to treat acute respiratory distress syndrome, glaucoma, kidney diseases, and others. The company was formerly known as ISMO Tech Solutions, Inc. and changed its name to Q BioMed Inc. in July 2015. Q BioMed Inc. was incorporated in 2013 and is based in New York, New York.
0.0001 USD
3.0000000015651188e-12 (0.000003%)
About
Description
Q BioMed Inc., a biomedical acceleration and development company, focuses on licensing, acquiring, and providing resources to life sciences and healthcare companies. The company offers Strontium Chloride SR89 and Metastron, a radiopharmaceutical therapeutic for the treatment of metastatic bone cancer pain. It is also developing Man-01, a pre-clinical lead candidate for the treatment of primary open angle glaucoma; QBM-001 for rare pediatric non-verbal autism spectrum disorder; and Uttroside-B for liver cancer. Q BioMed Inc. has a partnership with Mannin Research Inc. for the development of therapeutics to treat acute respiratory distress syndrome, glaucoma, kidney diseases, and others. The company was formerly known as ISMO Tech Solutions, Inc. and changed its name to Q BioMed Inc. in July 2015. Q BioMed Inc. was incorporated in 2013 and is based in New York, New York.
CIK
0001596062
ISIN
US74736N1054
CUSIP
74736N105
Address
366 Madison Avenue
Phone
212 588 0022
Country
US
Employee
3
IPO Date
Jun 17, 2015
Key Executives
Name
Title
Pay
Year Born
Mr. Ari Jatwes
Director of Finance
0
N/A
Mr. Denis D. Corin
Chairman, Chief Executive Officer & Pres...
300k
1973
Mr. William S. Rosenstadt
Chief Legal Officer, General Counsel & D...
300k
1968
As of December 31, 2024, the total employee count stands at 3, with compensation values reflecting the last fiscal year ending on that date. Pay encompasses salary, bonuses, etc., All figures are in USD.
